Article
Treatment with trastuzumab (Herceptin) boosts risk of heart failure or cardiomyopathy in breast cancer survivors, an observational study affirmed.
Women who received trastuzumab alone were 4.12 times more likely (95% CI 2.30 to 7.42) to go into heart failure after accounting for other factors, Erin Aiello Bowles, MPH, of the Group Health Research Institute in Seattle, and colleagues found.
Read the full story: http://bit.ly/RwF5RE
Source: MedPage Today
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.